Pompe Disease Therapeutic Market Research Report 2021

 

 

Pompe disease or also referred to as Glycogen storage disease type II is an autosomal recessive metabolic disorder that damages nerve cells and muscles through the entire body. It is typically caused because of the accumulation of glycogen in the lysosome, owing to deficiency of the lysosomal acid alpha-glucosidase enzyme.

Rising prevalence of Pompe disease is expected to operate a vehicle growth of the global Pompe Disease Therapeutic Market throughout the forecast period. Based on the National Organization for Rare Disorders (NORD), around 1 in 40,000 births in the U.S. and the Netherlands are affected with Pompe disease. Based on the same source, a current study revealed that their state of Missouri reported a greater prevalence of 1 in 5,463. Pompe disease can occur in a variety of populations and ethnic groups across the globe. Based on the Pompe Disease News, around 5,000 to 10,000 individuals have Pompe diseases worldwide. Consequently with this, the demand for new therapeutic treatment methods is increasing globally. Thus, these factors are expected to operate a vehicle growth of the global Pompe Disease Therapeutic Market throughout the forecast period. Furthermore, proactive initiatives taken by government authorities to produce and manufacture innovative products for the diagnosis and treatment of rare diseases are anticipated to propel the global Pompe disease therapeutic market growth on the forecast period.

However, the high cost related to treatment is anticipated to hinder the global Pompe Disease Therapeutic Market growth on the forecast period. Continuous research and development activities can present lucrative growth opportunities in the global Pompe disease therapeutic market in the near future. Among regions, North America is anticipated to witness significant growth in the global Pompe disease therapeutic market throughout the forecast period. This really is owing to the presence of robust healthcare infrastructure across the region. Furthermore, Europe is expected to register a powerful growth rate on the forecast period, owing to continuous research and development activities along with proactive support from government authorities to boost the healthcare sector.

Key companies operating in the global Pompe Disease Therapeutic Market are CENTOGENE AG, Amicus Therapeutics, Inc., AVROBIO, Inc., Sanofi, Valerion Therapeutics, Audentes Therapeutics, and Oxyrane.

For example, in June 2020, Sanofi announced outcomes of Phase III trial for the investigational enzyme replacement therapy (ERT) avalglucosidase alfa indicated for late-onset Pompe disease (LOPD) with clinically meaningful improvement.